Cargando…

Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies

[Image: see text] Utilizing natural antibodies to augment vaccine immunogenicity is a promising approach toward cancer immunotherapy. Anti-rhamnose (anti-Rha) antibodies are some of the most common natural anti-carbohydrate antibodies present in human serum. Therefore, rhamnose can be utilized as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Md Kamal, Vartak, Abhishek, Karmakar, Partha, Sucheck, Steven J., Wall, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103300/
https://www.ncbi.nlm.nih.gov/pubmed/29916701
http://dx.doi.org/10.1021/acschembio.8b00312
_version_ 1783349326707163136
author Hossain, Md Kamal
Vartak, Abhishek
Karmakar, Partha
Sucheck, Steven J.
Wall, Katherine A.
author_facet Hossain, Md Kamal
Vartak, Abhishek
Karmakar, Partha
Sucheck, Steven J.
Wall, Katherine A.
author_sort Hossain, Md Kamal
collection PubMed
description [Image: see text] Utilizing natural antibodies to augment vaccine immunogenicity is a promising approach toward cancer immunotherapy. Anti-rhamnose (anti-Rha) antibodies are some of the most common natural anti-carbohydrate antibodies present in human serum. Therefore, rhamnose can be utilized as a targeting moiety for a rhamnose-containing vaccine to prepare an effective vaccine formulation. It was shown previously that anti-Rha antibody generated in mice binds effectively with Rha-conjugated vaccine and is picked up by antigen presenting cells (APCs) through stimulatory Fc receptors. This leads to the effective uptake and processing of antigen and eventually presentation by major histocompatibility complex (MHC) molecules. In this article, we show that natural human anti-Rha antibodies can also be used in a similar mechanism and immunogenicity can be enhanced by targeting Rha-conjugated antigens. In doing so, we have purified human anti-Rha antibodies from human serum using a rhamnose affinity column. In vitro, human anti-Rha antibodies are shown to enhance the uptake of a model antigen, Rha-ovalbumin (Rha-Ova), by APCs. In vivo, they improved the priming of CD4+ T cells to Rha-Ova in comparison to non-anti-Rha human antibodies. Additionally, increased priming of both CD4+ and CD8+ T cells toward the cancer antigen MUC1-Tn was observed in mice that received human anti-Rha antibodies prior to vaccination with a rhamnose-modified MUC1-Tn cancer vaccine. The vaccine conjugate contained Pam(3)CysSK(4), a Toll-like receptor (TLR) agonist linked via copper-free cycloaddition chemistry to a 20-amino-acid glycopeptide derived from the tumor marker MUC-1 containing the tumor-associated carbohydrate antigen α-N-acetyl galactosamine (GalNAc). The primed CD8+ T cells released IFN-γ and killed tumor cells. Therefore, we have confirmed that human anti-Rha antibodies can be effectively utilized as a targeting moiety for making an effective vaccine.
format Online
Article
Text
id pubmed-6103300
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-61033002019-06-19 Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies Hossain, Md Kamal Vartak, Abhishek Karmakar, Partha Sucheck, Steven J. Wall, Katherine A. ACS Chem Biol [Image: see text] Utilizing natural antibodies to augment vaccine immunogenicity is a promising approach toward cancer immunotherapy. Anti-rhamnose (anti-Rha) antibodies are some of the most common natural anti-carbohydrate antibodies present in human serum. Therefore, rhamnose can be utilized as a targeting moiety for a rhamnose-containing vaccine to prepare an effective vaccine formulation. It was shown previously that anti-Rha antibody generated in mice binds effectively with Rha-conjugated vaccine and is picked up by antigen presenting cells (APCs) through stimulatory Fc receptors. This leads to the effective uptake and processing of antigen and eventually presentation by major histocompatibility complex (MHC) molecules. In this article, we show that natural human anti-Rha antibodies can also be used in a similar mechanism and immunogenicity can be enhanced by targeting Rha-conjugated antigens. In doing so, we have purified human anti-Rha antibodies from human serum using a rhamnose affinity column. In vitro, human anti-Rha antibodies are shown to enhance the uptake of a model antigen, Rha-ovalbumin (Rha-Ova), by APCs. In vivo, they improved the priming of CD4+ T cells to Rha-Ova in comparison to non-anti-Rha human antibodies. Additionally, increased priming of both CD4+ and CD8+ T cells toward the cancer antigen MUC1-Tn was observed in mice that received human anti-Rha antibodies prior to vaccination with a rhamnose-modified MUC1-Tn cancer vaccine. The vaccine conjugate contained Pam(3)CysSK(4), a Toll-like receptor (TLR) agonist linked via copper-free cycloaddition chemistry to a 20-amino-acid glycopeptide derived from the tumor marker MUC-1 containing the tumor-associated carbohydrate antigen α-N-acetyl galactosamine (GalNAc). The primed CD8+ T cells released IFN-γ and killed tumor cells. Therefore, we have confirmed that human anti-Rha antibodies can be effectively utilized as a targeting moiety for making an effective vaccine. American Chemical Society 2018-06-19 2018-08-17 /pmc/articles/PMC6103300/ /pubmed/29916701 http://dx.doi.org/10.1021/acschembio.8b00312 Text en Copyright © 2018 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Hossain, Md Kamal
Vartak, Abhishek
Karmakar, Partha
Sucheck, Steven J.
Wall, Katherine A.
Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies
title Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies
title_full Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies
title_fullStr Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies
title_full_unstemmed Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies
title_short Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies
title_sort augmenting vaccine immunogenicity through the use of natural human anti-rhamnose antibodies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103300/
https://www.ncbi.nlm.nih.gov/pubmed/29916701
http://dx.doi.org/10.1021/acschembio.8b00312
work_keys_str_mv AT hossainmdkamal augmentingvaccineimmunogenicitythroughtheuseofnaturalhumanantirhamnoseantibodies
AT vartakabhishek augmentingvaccineimmunogenicitythroughtheuseofnaturalhumanantirhamnoseantibodies
AT karmakarpartha augmentingvaccineimmunogenicitythroughtheuseofnaturalhumanantirhamnoseantibodies
AT sucheckstevenj augmentingvaccineimmunogenicitythroughtheuseofnaturalhumanantirhamnoseantibodies
AT wallkatherinea augmentingvaccineimmunogenicitythroughtheuseofnaturalhumanantirhamnoseantibodies